To decrease bisphosphonate (BP) dosage, increase bioavailability, and direct anticancer activity, investigators used the RALA (R-) peptide delivery system to form highly stable nanoparticles with the nitrogen containing BP, risedronate.
[Molecular Pharmaceutics]
